Investors can't figure out how to value the biotech ahead of the FDA approval of cabozantinib. So what: It's the curse of the biotechs that have a majority of their value tied up in their pipelines.
IMAGE SOURCE: BRON766 VIA WIKIMEDIA COMMONS. What:As it's done so many times recently,Exelixis ended down 10.4% on Tuesday on seemingly no news. So what: It's the curse of the biotechs that have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results